Note, BPC 157 has a particular angiogenic effect in wound healing [6,7,18,43,45,46] even in the hyponeural and hypocellular environment (i.e., tendon, fibrocartilage zone) [18,19,20,21,22] that makes the reparative process extremely difficult (since, on the other hand, BPC 157 may heal also corneal ulcer and maintains ocular transparency) [95], stronger angiogenic effect than the standard anti-ulcer agents [46] (note, BPC 157 inhibits the growth of several tumor cell lines and counteracts the effect of vascular endothelial growth factor (VEGF) [74]). The gene discussed is VEGFA; the disease is corneal ulcer.